Valuation: Glenmark Pharmaceuticals Limited

Market Cap 639B 6.73B 5.9B 5.43B 5.04B 9.56B 9.72B 65.13B 25.34B 315B 25.27B 24.72B 1,091B P/E 2026
44.2x
P/E 2027 * 27.3x
Enterprise Value 600B 6.32B 5.53B 5.1B 4.73B 8.97B 9.12B 61.13B 23.78B 296B 23.72B 23.2B 1,024B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.61x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day-0.26%
1 week+3.58%
Current month+2.75%
1 month+4.56%
3 months+7.61%
6 months+9.17%
Current year+11.29%
1 week 2,142.8
Extreme 2142.8
2,293.9
1 month 2,101
Extreme 2101
2,293.9
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 661
Extreme 661
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+3.58%+23.74%+238.93% 6.72B
-0.49%+1.53%+13.55%+82.58% 48.11B
-1.41%+5.55%+70.04%+116.16% 37.88B
-1.39%-0.16%-4.06%+42.16% 12.47B
+0.44%+2.83%+15.18%+96.06% 12B
+0.38%+2.76%+34.19%+120.25% 9.03B
-0.16%+1.91%+22.31%+47.95% 7.24B
+0.41%+2.01%+55.16%-3.74% 7.09B
-2.81%+17.66%-18.38%+20.93% 6.54B
-1.75%-2.06%+22.96%+132.38% 4.42B
Average -0.70%+3.71%+23.47%+89.37% 15.15B
Weighted average by Cap. -0.74%+3.85%+29.30%+91.00%

Financials

2026 2027 *
Net sales 153B 1.61B 1.41B 1.3B 1.21B 2.29B 2.33B 15.6B 6.07B 75.52B 6.05B 5.92B 261B 167B 1.76B 1.54B 1.42B 1.32B 2.49B 2.54B 17B 6.61B 82.3B 6.6B 6.45B 285B
Net income 20.53B 216M 189M 175M 162M 307M 312M 2.09B 814M 10.13B 812M 794M 35.05B 23.22B 245M 214M 197M 183M 347M 353M 2.37B 920M 11.45B 918M 898M 39.64B
Net Debt -39.29B -414M -362M -334M -310M -588M -598M -4B -1.56B -19.38B -1.55B -1.52B -67.08B -37.1B -391M -342M -315M -292M -555M -564M -3.78B -1.47B -18.3B -1.47B -1.43B -63.34B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
07/07/26 ₹2,264.90 -0.26% 770,737
06/07/26 ₹2,270.90 +2.71% 600,450
03/07/26 ₹2,211.00 +0.68% 632,010
02/07/26 ₹2,196.00 +1.58% 526,651
01/07/26 ₹2,161.90 -1.92% 455,357
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,264.90INR
Average target price
2,497.27INR
Spread / Average Target
+10.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock